30O Stock Overview
Engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
OncoTherapy Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.097 |
| 52 Week High | JP¥0.36 |
| 52 Week Low | JP¥0.067 |
| Beta | 0.47 |
| 1 Month Change | -34.46% |
| 3 Month Change | -48.13% |
| 1 Year Change | -6.73% |
| 3 Year Change | -81.70% |
| 5 Year Change | -85.74% |
| Change since IPO | -97.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 30O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -24.8% | -2.6% | -2.0% |
| 1Y | -6.7% | -13.2% | 6.8% |
Return vs Industry: 30O exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 30O underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 30O volatility | |
|---|---|
| 30O Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 30O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 30O's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 54 | Junichi Shimada | www.oncotherapy.co.jp |
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer.
OncoTherapy Science, Inc. Fundamentals Summary
| 30O fundamental statistics | |
|---|---|
| Market cap | €39.87m |
| Earnings (TTM) | -€6.87m |
| Revenue (TTM) | €2.93m |
13.6x
P/S Ratio-5.8x
P/E RatioIs 30O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 30O income statement (TTM) | |
|---|---|
| Revenue | JP¥479.00m |
| Cost of Revenue | JP¥1.17b |
| Gross Profit | -JP¥687.00m |
| Other Expenses | JP¥436.00m |
| Earnings | -JP¥1.12b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.13 |
| Gross Margin | -143.42% |
| Net Profit Margin | -234.45% |
| Debt/Equity Ratio | 0% |
How did 30O perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:25 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OncoTherapy Science, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |
| Toshiyuki Iwata | Mizuho Securities Co., Ltd. |